Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pelacarsen for slowing progression of calcific aortic valve stenosis in patients with elevated lipoprotein(a)
MOH_2023-05-21_012524Phase 2Recruiting
- Sponsor
- Novartis
- Start
- May 2023
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in aortic stenosis (AS) and calcific aortic stenosis (AS) comparing Pelacarsen 80 mg monthly with Matching placebo monthly (2 arms). Started May 2023; status: recruiting.
02
Drugs
pelacarsen
03
Conditions
aortic stenosis (AS)calcific aortic stenosis (AS)
Beyond the preview
Go deeper on MOH_2023-05-21_012524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-05-21_012524.